{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:28:09Z","timestamp":1787772489121,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>The expression of programmed cell death ligand1 (PDL1) is a research hotspot of immunotherapy. The treatment targeted for its expression has shown effectiveness in many tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of the study was to determine PD-L1 expression in urothelial carcinoma (UC) and to compare the PD-L1 expression in muscle invasive bladder carcinoma (MIBC) and upper urinary tract urothelial carcinoma (UTUC). The predictive value of CD8+ tumor-infiltrating lymphocyte (TIL) density for the diagnosis of PD-L1 positivity and the association between CD8+ TIL density and prognosis in MIBC were also explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Immunohistochemistry (IHC) staining for PD-L1 (SP263), CK5\/6, CK20, CD44, and p53 was carried out using a 3D Histech digital scanner to scan and determine CD8+ TIL density.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      122 patients received radical cystectomy, and the overall PD-L1 positivity was 34.43% (42\/122).  PD-L1 positivity in whole sections was higher than in tissue micro-array (TMA) (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). If multiple lesions were detected simultaneously, the number of patients with positive results increased from 42 to 49. The areas under the curve (AUCs) of CD8+ TIL density for the diagnosis of PD-L1 positivity were 0.739, 0.713, and 0.826. Univariate cox regression analysis demonstrated that high CD8+ TIL density and CD8\n                      <jats:sup>high<\/jats:sup>\n                      PDL1\n                      <jats:sup>+<\/jats:sup>\n                      were protective factors of overall survival (OS), and multivariate cox analyses showed that only CD8+ TIL density was an independent prognostic factor for OS. For UTUC, the overall PD-L1 expression was 40.0% (16\/40).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our study results emphasize the importance of detecting PD-L1 expression in multiple tumor lesions from the same patient. In MIBC, CD8+ TIL density could be used as a prognostic marker for predicting the status of PD-L1 expression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpm.ijpm_142_22","type":"journal-article","created":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T02:40:09Z","timestamp":1717036809000},"page":"702-707","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features"],"prefix":"10.4103","volume":"66","author":[{"given":"Yanfeng","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengdong","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00345-012-0946-6","article-title":"Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: How molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours","volume":"31","author":"Yates","year":"2013","journal-title":"World J Urol"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"123","DOI":"10.14740\/wjon1210","article-title":"Non-muscle invasive bladder cancer: A review of the current trend in Africa","volume":"10","author":"Cassell","year":"2019","journal-title":"World J Oncol"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for immunotherapy in bladder cancer: A moving target","volume":"5","author":"Aggen","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12885-018-4013-6","article-title":"Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ","volume":"18","author":"Beguinot","year":"2018","journal-title":"BMC Cancer"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00428-019-02618-5","article-title":"Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladde","volume":"475","author":"Rodriguez Pena","year":"2019","journal-title":"Virchows Arch"},{"key":"R8-20240829","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying Cancers Based on T-cell Infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"703.e1","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.euf.2016.11.011","article-title":"Programmed death-ligand 1 expression in upper tract urothelial carcinoma","volume":"3","author":"Skala","year":"2017","journal-title":"Eur Urol Focus"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/ejcts\/ezx492","article-title":"Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer","volume":"53","author":"Armani","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.anndiagpath.2018.03.007","article-title":"Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma","volume":"34","author":"L\u00f3pez","year":"2018","journal-title":"Ann Diagn Pathol"},{"key":"R14-20240829","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1002\/cam4.1686","article-title":"The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count","volume":"7","author":"Miyama","year":"2018","journal-title":"Cancer Med"}],"container-title":["Indian Journal of Pathology and Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_142_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:49:29Z","timestamp":1787770169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpm.ijpm_142_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpm.ijpm_142_22","relation":{},"ISSN":["0377-4929","0974-5130"],"issn-type":[{"value":"0377-4929","type":"print"},{"value":"0974-5130","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}